Tenax Therapeutics Inc. | Income Statement
Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
92.70
25.70
-
-
-
9
Cost of Goods Sold (COGS) incl. D&A
197.10
286.00
148.10
19.00
13.60
9
Gross Income
104.40
260.30
148.10
19.00
13.60
9
SG&A Expense
5,978.00
16,613.80
13,541.10
19,366.70
9,192.30
6,884.30
EBIT
6,082.40
16,874.10
13,689.30
19,385.60
9,205.90
6,893.30
Unusual Expense
248.00
721.80
794.30
32,966.90
192.40
-
Non Operating Income/Expense
1,153.00
266.40
57.90
74.50
0.20
0.20
Interest Expense
4,238.50
2,212.30
49.10
-
-
-
Pretax Income
9,415.80
19,541.80
14,081.80
51,886.00
8,839.70
6,813.40
Income Tax
-
-
-
7,962.10
-
-
Consolidated Net Income
9,415.80
19,541.80
14,081.80
43,923.90
8,839.70
6,813.40
Net Income
9,415.80
19,541.80
14,081.80
43,923.90
8,839.70
6,813.40
Net Income After Extraordinaries
9,415.80
19,541.80
14,081.80
43,923.90
8,839.70
6,813.40
Net Income Available to Common
10,373.90
25,345.20
14,081.80
43,923.90
8,839.70
14,144
EPS (Basic)
133.60
54.20
10.00
31.20
6.27
9.04
Basic Shares Outstanding
82.50
468.10
1,403.90
1,406.00
1,410.60
1,564.80
EPS (Diluted)
133.67
54.14
10.03
31.24
6.27
9.04
Diluted Shares Outstanding
88.00
468.10
1,403.90
1,406.00
1,410.60
1,564.80
EBITDA
5,928.40
16,717.90
13,541.10
19,366.70
9,192.30
6,884.30
Non-Operating Interest Income
-
-
393.00
392.00
174.00
80
Preferred Dividends
958.10
5,803.40
-
-
-
7,330.60
About Tenax Therapeutics
View Profile
